Bernatsky S, Clarke A, Ramsey-Goldman R
Curr Rheumatol Rep. 2002; 4(4):351-8.
PMID: 12126588
DOI: 10.1007/s11926-002-0045-6.
Mowbray J
Proc R Soc Med. 1970; 63(10):1067-8.
PMID: 5483519
PMC: 1811627.
Harris J, Jessop J, Chaput de Saintonge D
Br Med J. 1971; 4(5785):463-4.
PMID: 5125282
PMC: 1799668.
DOI: 10.1136/bmj.4.5785.463.
DENMAN A
Clin Exp Immunol. 1969; 5(3):217-49.
PMID: 4980325
PMC: 1579119.
Penn I, HAMMOND W, BRETTSCHNEIDER L, Starzl T
Transplant Proc. 1969; 1(1):106-12.
PMID: 4944206
PMC: 2845467.
Renal disease in (NZB x NZW) F1 mice treated with antilymphocytic antibody. II. Effects of restoration with isogeneic, allogeneic, and xenogeneic lymphoid cells.
DENMAN A, Russell A, Denman E
Clin Exp Immunol. 1970; 6(6):841-59.
PMID: 4920551
PMC: 1712810.
Malignant lymphomas in transplantation patients: a review of the world experience.
Penn I, Starzl T
Int Z Klin Pharmakol Ther Toxikol. 1970; 3(1):49-54.
PMID: 4909379
PMC: 2965461.
Nephrotic syndrome due to primary renal disease in adults: II. A controlled trial of prednisolone and azathioprine.
SHARPSTONE P, Ogg C, Cameron J
Br Med J. 1969; 2(5656):535-9.
PMID: 4890207
PMC: 1983486.
DOI: 10.1136/bmj.2.5656.535.
Lymphocyte responses to phytohemagglutinin in rheumatoid arthritis and glomerulonephritis and the effects of immunosuppression.
Griswold W, McIntosh R
Experientia. 1973; 29(5):606-7.
PMID: 4730305
DOI: 10.1007/BF01926694.
Immunosuppression and malignancy.
Br Med J. 1972; 3(5829):713-4.
PMID: 4562175
PMC: 1788691.
Azathioprine in ulcerative colitis: an interim report on a controlled therapeutic trial.
Jewell D, TRUELOVE S
Br Med J. 1972; 1(5802):709-12.
PMID: 4552464
PMC: 1787615.
DOI: 10.1136/bmj.1.5802.709.
Studies on thymus products. IV. Absence of serum 'thymic activity' in adult NZB and (NZB x NZW) F1 mice.
Bach J, Dardenne M, SALOMON J
Clin Exp Immunol. 1973; 14(2):247-56.
PMID: 4541554
PMC: 1553790.
The disease of the NZB mouse. I. Examination of ovum fusion derived tetraparental NZB:CFW chimaeras.
Barnes R, Tuffrey M, Kingman J, Thornton C, Turner M
Clin Exp Immunol. 1972; 11(4):605-28.
PMID: 4404414
PMC: 1553692.
Iatrogenic alterations of immunologic surveillance in man and their influence on malignancy.
Starzl T, Penn I, Putnam C, Groth C, Halgrimson C
Transplant Rev. 1971; 7:112-45.
PMID: 4401720
PMC: 2980327.
DOI: 10.1111/j.1600-065x.1971.tb00465.x.
Tumour development following immunosuppression.
Allison A
Proc R Soc Med. 1970; 63(10):1077-80.
PMID: 4320709
PMC: 1811685.
Further implication of murine leukemia-like virs in the disorders of NZB mice.
MELLORS R, Aoki T, HUEBNER R
J Exp Med. 1969; 129(5):1045-62.
PMID: 4305180
PMC: 2138640.
DOI: 10.1084/jem.129.5.1045.
[Immunosuppression, genesis and growth of malignant tumours].
Reis H
Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1972; 78(1):42-50.
PMID: 4264377
DOI: 10.1007/BF00284311.
Monoclonal macroglobulinemia in NZB-NZW F1 mice.
Sugai S, Pillarisetty R, Talal N
J Exp Med. 1973; 138(4):989-1002.
PMID: 4200650
PMC: 2180563.
DOI: 10.1084/jem.138.4.989.
Immunosuppression and neoplasia. II. Is deficient immunesurveillance the only mechanism by which immunosuppression promotes neoplasia? A speculative review.
Gleichmann E, Gleichmann H
Klin Wochenschr. 1973; 51(6):260-5 concl.
PMID: 4144595
DOI: 10.1007/BF01467813.
Differential effects of 6-mercaptopurine and cyclophosphamide on autoimmune phenomena in NZB mice.
Lemmel E, Hurd E, ZIFF M
Clin Exp Immunol. 1971; 8(2):355-62.
PMID: 4102260
PMC: 1712938.
